Sprint Bioscience is a pharmaceutical company focused on developing innovative drug candidates that can contribute to new treatments for cancer.

Using a fragment-based drug development (FBDD) strategy, we develop our programs in a time- and resource-efficient manner. We enter into partnerships with global pharmaceutical companies during the pre-clinical phase for further development through the regulatory development stages.

Our portfolio is focused on tumor microenvironment, tumor metabolism, and immuno-oncology for the treatment of cancer. We aim to have a broad portfolio and develop multiple programs in parallel.